Identification of Amino Acid Residues That Form Part of the Ligand-binding Pocket of Integrin α5β1

A. Paul Mould, Louise Burrows, Martin J. Humphries

Journal of Biological Chemistry · 1998 · 54 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

Arg-Arg-Glu-Thr-Ala-Trp-Ala (RRETAWA) is a novel ligand peptide for integrin α5β1, which blocks α5β1-mediated cell adhesion to fibronectin (Koivunen, E., Wang, B., and Ruoslahti, E. (1994)J. Cell Biol. 124, 373–380). Here we have localized the binding site for RRETAWA on α5β1 using inhibitory monoclonal antibodies (mAbs) and site-directed mutagenesis. A cyclic peptide containing this sequence (*CRRETAWAC*) had little effect on the binding of most anti-α5 and anti-β1 mAbs to α5β1 but completely blocked binding of the anti-α5 mAb 16 in a directly competitive manner. Hence, the binding site of RRETAWA appears to closely overlap with the epitope of mAb 16. *CRRETAWAC* also acted as a direct competitive inhibitor of the binding of Arg-Gly-Asp (RGD)-containing fibronectin fragments to α5β1, suggesting that the binding site for RRETAWA is also closely overlapping with that for RGD. However, differences between the binding sites of RRETAWA and RGD were apparent in that (i) RGD peptides allosterically inhibited the binding of mAb 16 to α5β1, and (ii) several mAbs that perturbed binding of α5β1 to RGD had little effect on binding of α5β1 to RRETAWA. A double mutation in α5 (S156G/W157S) blocked the interaction of both RRETAWA and mAb 16 with α5β1 but had no effect on fibronectin binding or on the binding of other anti-α5 mAbs. Ser156-Trp157 is located near the apex of a putative loop region on the upper surface of a predicted β-propeller structure formed by the NH2-terminal repeats of α5. Our findings suggest that this sequence forms part of the ligand-binding pocket of α5β1. Furthermore, as Ser156-Trp157 is unique to the α5 subunit, it may be responsible for the specific recognition of RRETAWA by α5β1. Arg-Arg-Glu-Thr-Ala-Trp-Ala (RRETAWA) is a novel ligand peptide for integrin α5β1, which blocks α5β1-mediated cell adhesion to fibronectin (Koivunen, E., Wang, B., and Ruoslahti, E. (1994)J. Cell Biol. 124, 373–380). Here we have localized the binding site for RRETAWA on α5β1 using inhibitory monoclonal antibodies (mAbs) and site-directed mutagenesis. A cyclic peptide containing this sequence (*CRRETAWAC*) had little effect on the binding of most anti-α5 and anti-β1 mAbs to α5β1 but completely blocked binding of the anti-α5 mAb 16 in a directly competitive manner. Hence, the binding site of RRETAWA appears to closely overlap with the epitope of mAb 16. *CRRETAWAC* also acted as a direct competitive inhibitor of the binding of Arg-Gly-Asp (RGD)-containing fibronectin fragments to α5β1, suggesting that the binding site for RRETAWA is also closely overlapping with that for RGD. However, differences between the binding sites of RRETAWA and RGD were apparent in that (i) RGD peptides allosterically inhibited the binding of mAb 16 to α5β1, and (ii) several mAbs that perturbed binding of α5β1 to RGD had little effect on binding of α5β1 to RRETAWA. A double mutation in α5 (S156G/W157S) blocked the interaction of both RRETAWA and mAb 16 with α5β1 but had no effect on fibronectin binding or on the binding of other anti-α5 mAbs. Ser156-Trp157 is located near the apex of a putative loop region on the upper surface of a predicted β-propeller structure formed by the NH2-terminal repeats of α5. Our findings suggest that this sequence forms part of the ligand-binding pocket of α5β1. Furthermore, as Ser156-Trp157 is unique to the α5 subunit, it may be responsible for the specific recognition of RRETAWA by α5β1. Arg-Gly-Asp Arg-Arg-Glu-Thr-Ala-Trp-Ala cyclo-(Gly-Ala-Cys-Arg-Arg-Glu-Thr-Ala-Trp-Ala-Cys-Ala-Gly) monoclonal antibody phosphate-buffered saline bovine serum albumin enzyme-linked immunosorbent assay 2,2′-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid) metal ion-dependent adhesion site. Integrin α5β1 is a widely distributed cell surface receptor for the extracellular matrix glycoprotein fibronectin. The cell-binding domain of fibronectin contains a number of repeated modules termed fibronectin type III repeats. An Arg-Gly-Asp (RGD)1 sequence in the 10th type III repeat is the major binding site for α5β1 (1Pierschbacher M.D. Ruoslahti E. Nature. 1984; 309: 30-33Crossref PubMed Scopus (2978) Google Scholar, 2Yamada K.M. Kennedy D.W. J. Cell Biol. 1984; 99: 29-36Crossref PubMed Scopus (339) Google Scholar), although an additional “synergy” sequence in the ninth type III repeat is also recognized by this integrin (3Aota S. Nomizu M. Yamada K.M. J. Biol. Chem. 1994; 269: 24756-24761Abstract Full Text PDF PubMed Google Scholar, 4Mould A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). Recently, a novel ligand sequence for α5β1, Arg-Arg-Glu-Thr-Ala-Trp-Ala(RRETAWA), was identified from a CX 7C phage display library (5Koivunen E. Wang B. Ruoslahti E. J. Cell Biol. 1994; 124: 373-380Crossref PubMed Scopus (297) Google Scholar). Peptides containing this sequence support cell adhesion directly, and antagonize α5β1-mediated adhesion of cells to fibronectin. RRETAWA appears to be specific to human α5β1, as it is not recognized by other RGD-dependent integrins or by murine α5β1. Although the RRETAWA sequence appears unrelated to RGD, the binding sites for RRETAWA and RGD on α5β1 were proposed to be closely overlapping because peptides containing the RRETAWA sequence blocked the recognition of RGD by α5β1 and vice versa (5Koivunen E. Wang B. Ruoslahti E. J. Cell Biol. 1994; 124: 373-380Crossref PubMed Scopus (297) Google Scholar). The NH2-terminal half of integrin α subunits consist of a seven-fold repeated unit of about 60 amino acid residues. Repeats 4–7 (or in some integrins repeats 5–7) contain putative divalent cation binding sites (6Tuckwell Humphries M.J. J. PubMed Scopus Google Scholar). of integrin α subunits contain an or domain of about amino acid between the and repeats. the contains the major sites in ligand binding Humphries M.J. Full Text PDF PubMed Scopus Google Scholar, M.J. Cell Biol. PubMed Google Scholar). binding sites in integrins as have localized to in the NH2-terminal of both α and subunits M.J. Cell Biol. PubMed Google Scholar, Y. Irie A. Biol. 1997; PubMed Scopus Google Scholar). The NH2-terminal repeats of α subunits predicted to have a structure Humphries M.J. A. Cell 1994; PubMed Scopus Google Scholar), and to a β-propeller S. A. 1997; PubMed Scopus Google Scholar). of the contains by of that the on the upper or of the an it was that several putative loop on the upper surface of the β-propeller with the in ligand recognition by and also the binding of inhibitory antibodies (mAbs) A. Takada Y. S. A. 1997; PubMed Scopus Google Scholar). predicted loop on the upper surface of the α5 β-propeller with the from binding of inhibitory anti-α5 mAbs A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). The region of the that in ligand recognition predicted to have a Full Text PDF PubMed Scopus Google Scholar, M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Humphries M.J. 1997; PubMed Scopus Google the of this domain to ligand binding a metal ion-dependent adhesion site Full Text PDF PubMed Scopus Google Scholar, M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Humphries M.J. 1997; PubMed Scopus Google Scholar, J. 1997; 99: PubMed Google Scholar). A for the of the α and ligand-binding sites A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, M.J. Cell Biol. PubMed Google J. 1997; 99: PubMed Google Scholar). However, the amino acid that in ligand recognition have inhibitory mAbs be to the binding between integrin and ligand A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, A.P. Humphries M.J. J. Google Scholar). Here we have the of RRETAWA recognition using inhibitory anti-α5 and anti-β1 in with site-directed mutagenesis. that the binding site for RRETAWA is overlapping with the epitope of the anti-α5 mAb 16 and also with that in recognition of RGD. mAb 16 not to murine α5β1, we in predicted loop on the upper surface of the human α5 β-propeller with the from murine α5. A double mutation (S156G/W157S) was to binding of mAb 16. The mutation also perturbed binding of α5β1 to RRETAWA. Our specific amino acid in recognition of RRETAWA and that that with RGD may be located in the or in a closely region of the findings also support the proposed of the ligand-binding pocket of α5β1 A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, M.J. Cell Biol. PubMed Google Scholar). mAbs 16 and the human α5 subunit, and mAb the human were from Yamada of and were from and α5 mAbs and were from and mAbs and were from and The antibodies were as and were from The peptides and were using on an peptide and as M.J. A. Yamada K.M. J. Cell Biol. PubMed Scopus Google Scholar). was using to J. Chem. Scopus Google Scholar), and by on were on an or were from was from Integrin α5β1 was from human as A.P. Humphries M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). fragments of the cell-binding domain of fibronectin were as Aota S. Yamada K.M. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google and using and as A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). mAb in was with an of and for The was several of to The was for and was in of this of in of was The was for and *CRRETAWAC* in of was of the for peptide and were by The was for and in α5β1 a of was with containing and were to the of a were and were blocked for with of were with of containing of mAbs or of in were to the in the or of The was for antibody was and the were with A. antibody was by of or in A for were with and was using The of was using a were the of in which the effect of in the assay with or was A was the the of mAb with integrin or were a of peptides as direct competitive or of mAb 16 the of antibody binding of peptide was as a of mAb 16 and The of peptide to antibody and the of were by as A.P. Humphries M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). of was using binding was using a of A.P. Humphries M.J. J. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). Here a assay was in which ligand of was to the and integrin of was to from the were with or for blocked as and with of A. of α5β1 in A were to the with or mAbs or of The was for integrin was and the were with A. of mAb in A were to the for The were in and of in A for were with and was using were the of the the of binding was by the of antibody or integrin binding to with were from the for or is of A of human α5 in was PubMed Scopus Google was using the to the The was containing α5 to the The of the mutation was by cells S. M. J. Cell Biol. PubMed Scopus Google from of were using in in to a of in and cells were of or α5 was and the cells were on for were and and on for with and amino was and the cells were and in a containing the was with were The cell was with mAb mAb that a epitope on the α5 and with to for cells α5. The of and α5 was by in using mAb or α5 were by to The of cells to a of anti-α5 mAbs was using using or as or cells with or human α5 were using in with for in the and in the with to a of were in were for 60 with of or with and sites on the for cell adhesion were blocked for with of The was by and the were with B. of the cells in were to the and for in a of the effect of anti-α5 mAbs on cell cells were with mAbs for to the the for cells in with were by direct of of for or cells from were by the with of and the cells were as for The was the were with of and cells were with as A.P. Humphries M.J. J. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). The of was using a was in and to of the was from is of have that recognition of fibronectin by α5β1 the binding of inhibitory anti-α5 and A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, A.P. Humphries M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), and that mAbs be to ligand recognition of RRETAWA in the binding of inhibitory anti-α5 or anti-β1 we the effect of a of the cyclic peptide (*CRRETAWAC*) (5Koivunen E. Wang B. Ruoslahti E. J. Cell Biol. 1994; 124: 373-380Crossref PubMed Scopus (297) Google on the binding of a of mAbs to α5β1. and were as anti-α5 and anti-β1 The that binding of the anti-α5 mAb 16 to α5β1 was completely blocked by The binding of other anti-α5 mAbs was or *CRRETAWAC* had a inhibitory effect on the binding of the anti-β1 mAbs and of of mAb 16 binding by *CRRETAWAC* was on the of divalent binding was inhibited or was in the assay A of was in the of and the peptide was in the of findings suggest that the of mAb 16 binding is to recognition of RRETAWA by α5β1, which to be (5Koivunen E. Wang B. Ruoslahti E. J. Cell Biol. 1994; 124: 373-380Crossref PubMed Scopus (297) Google Scholar). The divalent cation for the interaction of RRETAWA with α5β1 to for fibronectin A.P. Humphries M.J. J. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). the *CRRETAWAC* peptide acted as a direct competitive inhibitor or as an inhibitor of mAb 16 we the inhibitory effect of *CRRETAWAC* on mAb 16 binding a of mAb The that antibody binding be completely inhibited peptide and that the of *CRRETAWAC* for of mAb 16 binding in with the antibody for a in antibody as be for a direct competitive of *CRRETAWAC* were that *CRRETAWAC* directly with mAb 16 for binding to α5β1. Hence, it appears that the binding site for RRETAWA on α5β1 is overlapping with the epitope of mAb 16. the between the binding sites for RRETAWA and RGD on α5β1, we the inhibitory effect of *CRRETAWAC* on the binding of a fibronectin to α5β1. Aota S. Yamada K.M. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), contains the RGD site in the 10th type III The that *CRRETAWAC* peptide completely blocked the binding of to α5β1, and the of *CRRETAWAC* for of binding in with the of for a in as be RRETAWA acted as a direct competitive inhibitor of RGD of were that RRETAWA directly with fibronectin for binding to α5β1. Although the fibronectin in also contains the region of the ninth type III were with a Aota S. Yamada K.M. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), in which the sequence is with an sequence from the type III repeat not Hence, it appears that the binding site for RRETAWA directly with that of RGD. is with the of peptides containing the RRETAWA sequence to the recognition of RGD by α5β1 and vice versa (5Koivunen E. Wang B. Ruoslahti E. J. Cell Biol. 1994; 124: 373-380Crossref PubMed Scopus (297) Google Scholar). the between RRETAWA and RGD, we recognition of RGD by α5β1 the binding of mAb or other anti-α5 mAbs. The peptide was as a as this peptide to have to fibronectin fragments that the sequence A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). The that mAb 16 binding to α5β1 was inhibited by with A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar), this peptide had no effect on the binding of other anti-α5 mAbs but the binding of inhibitory anti-β1 mAbs. RGD peptide acted as a direct competitive inhibitor or as an inhibitor of mAb 16 we the effect of on mAb 16 binding a of antibody The that the of RGD peptide for of antibody binding was the for of and the of with antibody with a direct competitive and suggest that is an inhibitor of mAb 16 of were that allosterically inhibited mAb 16 binding to α5β1. Hence, and *CRRETAWAC* of of mAb 16 of were not to the in between and or to differences in the of the peptides for binding to α5β1, because a cyclic RGD peptide of and to *CRRETAWAC* the of as on mAb 16 binding not it appears that the binding site of RGD not directly overlap with the mAb 16 and the binding sites for RRETAWA and RGD, although of the effect of on the binding of mAb 16 to α5β1. binding of mAb 16 was of a of mAb or the of peptide for of mAb binding and for and mAb of and of the in A. of an differences between the of binding of RRETAWA and RGD to α5β1, we the binding of RRETAWA and RGD to α5β1 was inhibited by the or by mAbs. the *CRRETAWAC* peptide was to a and a assay was in which the ligand was on the and binding of α5β1 from the was using a anti-α5 mAb S. Yamada K.M. PubMed Scopus Google Scholar). an we the Aota S. Yamada K.M. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), which the and of α5β1 binding not The A and that the binding of α5β1 to both and was blocked by mAb 16. other anti-α5 mAbs and blocked binding to both However, anti-α5 mAb inhibited recognition of the fibronectin but not an anti-α5 mAb to recognition of the region but not the RGD sequence of fibronectin A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar), also not binding of α5β1 to anti-β1 mAb and which perturbed recognition of were binding of α5β1 to that the binding sites of RRETAWA and RGD on α5β1 overlapping but not binding of α5β1 to was completely blocked by *CRRETAWAC* or but not by binding of α5β1 to was blocked by or *CRRETAWAC* of α5β1 to both was in the of anti-α5 mAbs to in the and NH2-terminal repeats of putative loop on the upper surface of the β-propeller structure formed by the NH2-terminal repeats A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). mAb 16 not with murine α5β1, we the of in loop with the in the murine α5 to amino acid that part of the mAb 16 epitope and α5 subunits were on the surface of S. M. J. Cell Biol. PubMed Scopus Google Scholar). A double was to mAb 16 binding in this region of α5 not mAb 16 The of be A. and M. J. in The mutation had no effect on the binding of other anti-α5 suggesting that the epitope of mAb 16 and also that the mutation not in the structure of of anti-α5 mAbs to type and type or human α5 subunits were on the of cells with and the of anti-α5 mAbs to the cells was by The in the the of cells in a of the cells to the of the antibodies with in a type or human α5 subunits were on the of cells with and the of anti-α5 mAbs to the cells was by The in the the of cells in a of the cells to the of the antibodies with the receptor to the fibronectin as cells α5β1 that the mutation not recognition of the RGD although cells the receptor to cells the integrin to to this Hence, the to part binding site of RRETAWA. this we have to the site of interaction of a novel ligand sequence RRETAWA with α5β1. Our major findings as (i) The binding site of RRETAWA appears to directly overlap with the epitope of the inhibitory anti-α5 mAb 16. (ii) The binding site of RRETAWA appears to be overlapping but is the binding site of RGD. amino acid in a putative loop region of the α5 to part of the binding site of RRETAWA and the mAb 16 to support and a of the ligand-binding pocket of α5β1 A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, M.J. Cell Biol. PubMed Google Scholar), and also an for the of RRETAWA for human α5β1. The binding site of RRETAWA to be directly overlapping with the mAb 16 epitope because the *CRRETAWAC* peptide acted as a direct competitive inhibitor of mAb 16 other inhibitory mAbs ligand binding an of antibody suggesting that the of mAbs to but not directly overlapping with the ligand binding sites A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, A.P. Humphries M.J. J. Google A.P. Humphries M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). The epitope of mAb 16 appears from that of other anti-α5 mAbs because mAb 16 binding was inhibited by support of this mAb 16 was the anti-α5 mAb binding was perturbed by RGD and the mutation blocked mAb 16 of mAb 16 binding by *CRRETAWAC* was specific because it was on the of divalent in the RRETAWA sequence the of the peptide to mAb 16 and J. is to that the binding of mAb 16 to α5β1, although by divalent A.P. Takada Y. Humphries M.J. J. PubMed Scopus Google Scholar), is not Hence, the of binding of mAb 16 and *CRRETAWAC* to α5β1 not and mAb 16 not to a of antibodies as J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). that the binding sites of RRETAWA and the mAb 16 epitope directly overlapping from the that the mutation perturbed the binding of both mAb 16 and RRETAWA to α5β1, suggesting that part of the mAb 16 epitope and the binding site of Our also that *CRRETAWAC* acted as a direct competitive inhibitor of the binding of fibronectin fragments to α5β1. Hence, the binding site of RRETAWA appears to be overlapping with that of RGD. support of several anti-α5 mAb blocked the recognition of both RRETAWA and RGD by α5β1. However, several of that the binding sites were not (i) RGD peptides acted as of mAb 16 binding *CRRETAWAC* acted a direct competitive (ii) recognition of RGD peptides by a of anti-β1 mAb *CRRETAWAC* 4Mould A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google and A.P. Humphries M.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, and this several mAbs that RGD recognition anti-β1 mAbs as and have little or no effect on recognition of and the mutation perturbed binding of α5β1 to RRETAWA but had no effect on recognition of RGD. A between the binding of RRETAWA and RGD to α5β1 is that the appears to little to recognition of it the major in recognition of RGD A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). to the of anti-α5 we we a in which putative loop on the upper surface of the α5 β-propeller were with the from the A of this is that loop of mAb for by in on we the of a number of in human α5 with the from murine α5. Furthermore, as sites in recognition of RGD be from human to we predicted that the integrins the to fibronectin. Our that the mutation blocked binding of mAb 16 but not of other anti-α5 the of the mutation in the cells the integrin to an of fibronectin to a as cells the the mutation completely blocked the of the integrin to RRETAWA. α5β1 not to to RRETAWA (5Koivunen E. Wang B. Ruoslahti E. J. Cell Biol. 1994; 124: 373-380Crossref PubMed Scopus (297) Google Scholar), the sequence appears to part of the specific binding site for RRETAWA on human α5β1. with the of RRETAWA for human α5β1, the sequence is not in this in other integrin α A that the epitope of mAb 16 may in a region of the α5 subunit, as a mutation blocked the binding of this antibody A. Takada Y. J. PubMed Scopus Google Scholar). However, this is in α on structure may this mutation perturbed mAb 16 it is that this to the mAb 16 epitope because it is predicted to in the loop of the NH2-terminal and to be in to the loop that contains the not some anti-α5 mAbs as recognition of RGD although binding is not inhibited by RGD However, we have that the of antibodies to the between the α5 and subunits A.P. Takada Y. Humphries M.J. J. PubMed Scopus Google Scholar). the sites have to or near this A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, M.J. Cell Biol. PubMed Google Scholar), antibodies may the interaction of fibronectin fragments with α5β1 by mAbs may a for recognition of RGD A.P. J. Cell PubMed Google Scholar). A may also for the of some of mAbs to recognition of RRETAWA. the epitope of a mAb that recognition of the region of fibronectin not to the A.P. Takada Y. Humphries M.J. J. PubMed Scopus Google Scholar). on of fibronectin binding to α5β1, and the structure of the cell-binding domain of fibronectin Full Text Full Text PDF PubMed Scopus Google Scholar), we proposed that sites in ligand recognition by α5β1 were located in on the surface of the α5 β-propeller structure and on the of the region of the subunit, and that modules in the of α5β1 A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, M.J. Cell Biol. PubMed Google Scholar). Our findings to and the Ser156-Trp157 is predicted to near the apex of the loop of the NH2-terminal on the upper surface of the α5 Our this region of α5 as part of the ligand-binding of the mAb 16 in with that it to the between the α5 β-propeller and the putative A.P. Takada Y. Humphries M.J. J. PubMed Scopus Google Scholar), support to the The loop that contains Ser156-Trp157 from the α it in to the region of the loop also appears to an in integrin A.P. Takada Y. Humphries M.J. J. PubMed Scopus Google Scholar). the region of the α5 identified as part of the ligand-binding pocket of α5β1 is located the as the is in integrin subunits that this may be between the of ligand binding in containing and containing An that the cation binding sites in integrin α subunits directly with ligand peptides Nature. Scopus Google Scholar). However, the cation binding sites in the α5 to directly in ligand recognition because predicted to on the surface of the a from the on the upper surface of the in the and repeats. also an for sites A. Biol. 1997; PubMed Scopus Google Scholar). Although the RGD sequence of fibronectin is recognized by the A.P. Askari J.A. Aota S. Yamada K.M. Irie A. Takada Y. Mardon H.J. Humphries M.J. J. Biol. Chem. 1997; 272: 17283-17292Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar), it is that the also a in recognition of RGD because a of integrins this RRETAWA directly with RGD for binding to α5β1, on the in recognition of RGD predicted to to in RRETAWA in the loop of the NH2-terminal repeat or in a closely A that and of α5 in A. Takada Y. J. PubMed Scopus Google Scholar). predicted to be located in the loop of the NH2-terminal which to the An is that RRETAWA with RGD for binding to the region of the A is in this and it proposed that an in the ligand or to the divalent the site Full Text PDF PubMed Scopus Google Scholar, J. 1997; 99: PubMed Google Scholar). support of this we that the of RRETAWA is for may also the divalent of RGD and RRETAWA for binding to α5β1. the of *CRRETAWAC* to α5β1 and to the RGD and RRETAWA binding Yamada and S. Aota for the fibronectin and and mAbs and J. Humphries and for peptide for for and for

References

31